Top 50 Life Science VC Funds & Investors in United Kingdom (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Parkwalk Advisors
VC Fund
|
17 | United Kingdom, United States, Philippines | Seed, Series A, Series B | Biotechnology, Health Care, Software | $982k–$46M |
|
Oxford Science Enterprises
VC Fund
|
14 | United Kingdom, United States, Finland | Seed, Series A, Series B | Health Care, Biotechnology, Software | $1.3M–$168M |
|
UK Innovation & Science Seed Fund
VC Fund
|
14 | United Kingdom, United States | Seed, Series A | Biotechnology, Health Care, Medical | $393k–$14M |
|
SOSV
VC Fund
|
13 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
Development Bank of Wales
VC Fund
|
10 | United Kingdom, Australia, United States | Seed, Debt Financing | Software, Health Care, Biotechnology | $18k–$3.7M |
|
Sofinnova Partners
VC Fund
|
9 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6M–$120M |
|
IQ Capital
VC Fund
|
8 | United Kingdom, United States, Germany | Seed, Series A | Software, Artificial Intelligence, Machine Learning | $1.3M–$44M |
|
24 Haymarket
VC Fund
|
7 | United Kingdom, United States | Seed, Series A | Health Care, Software, Information Technology | $714k–$16M |
|
Scottish Enterprise
VC Fund
|
7 | United Kingdom, United States, Japan | Grant, Seed | Biotechnology, Software, Health Care | $104k–$4.8M |
|
GM&C Life Sciences Fund
VC Fund
|
7 | United Kingdom, Italy, Germany | Seed, Series A | Health Care, Biotechnology, Medical | $65k–$4.1M |
|
Syncona Partners LLP
VC Fund
|
7 | United Kingdom, United States, Switzerland | Series A, Series B, Seed | Biotechnology, Medical, Health Care | $1.8M–$131M |
|
Future Planet Capital
VC Fund
|
6 | United Kingdom, United States, Spain | Seed, Convertible Note | Biotechnology, Health Care, Software | $897k–$7.9M |
|
Archangels
VC Fund
|
6 | United Kingdom, United States | Seed, Series A | Software, Biotechnology, Health Care | $1.3M–$8.3M |
|
Newable Private Investing
VC Fund
|
6 | United Kingdom, United States | Seed, Series A | Software, Health Care, Biotechnology | $196k–$5.2M |
|
Selvedge Venture
VC Fund
|
6 | United Kingdom, Singapore | Seed, Pre-Seed, Series A | Health Care, Biotechnology, Life Science | $1.1M–$30M |
|
Angels in MedCity
VC Fund
|
6 | United Kingdom, United States | Seed, Angel | Health Care, Biotechnology, Medical | $458k–$880k |
|
Kindred Capital
VC Fund
|
6 | United Kingdom, United States, Germany | Seed, Series A, Series B | Software, Biotechnology, Health Care | $1.5M–$73M |
|
APEX Ventures
VC Fund
|
5 | Germany, United Kingdom, Austria | Seed, Series A, Pre-Seed | Artificial Intelligence, Software, Health Care | $511k–$28M |
|
Techstart Ventures
VC Fund
|
5 | United Kingdom, Ireland, United States | Seed, Pre-Seed | Software, Information Technology, Health Care | $183k–$3.5M |
|
SR One
VC Fund
|
5 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.7M–$150M |
|
IP Group
VC Fund
|
5 | United Kingdom, United States, Australia | Seed, Series A | Health Care, Biotechnology, Therapeutics | $393k–$23M |
|
Epidarex Capital
VC Fund
|
5 | United Kingdom, United States, Germany | Series A, Seed, Series B | Biotechnology, Health Care, Therapeutics | $531k–$55M |
|
Scottish Investment Bank
VC Fund
|
5 | United Kingdom, United States, France | Seed, Series A | Software, Biotechnology, Health Care | $327k–$7M |
|
Maven Capital Partners
VC Fund
|
5 | United Kingdom, United States, Germany | Seed, Series A | Software, Information Technology, SaaS | $655k–$25M |
|
Deepbridge Capital
VC Fund
|
5 | United Kingdom, Australia, Singapore | Seed, Series A | Health Care, Biotechnology, Medical | $152k–$15M |
|
Oxford Capital
VC Fund
|
4 | United Kingdom, United States, France | Seed, Series A | Software, Health Care, Biotechnology | |
|
Google Ventures
VC Fund
|
4 | United States, United Kingdom, Israel | Series A, Series B, Seed | Software, Health Care, Biotechnology | $1M–$107M |
|
Angels 5K
VC Fund
|
4 | United Kingdom | Seed, Angel | Biotechnology, Software, Medical | $79k–$1.3M |
|
AlbionVC
VC Fund
|
4 | United Kingdom, United States, France | Series A, Seed | Software, Information Technology, Health Care | $2.2M–$20M |
|
Playfair Capital
VC Fund
|
4 | United Kingdom, United States, France | Seed, Series A, Pre-Seed | Software, Artificial Intelligence, E-Commerce | $700k–$20M |
|
Formic Ventures
VC Fund
|
4 | United States, United Kingdom, Hong Kong | Seed, Series A | Biotechnology, Health Care, Biopharma | $1.3M–$61M |
|
Octopus Ventures
VC Fund
|
4 | United Kingdom, United States, Germany | Series A, Seed, Series B | Software, Health Care, Information Technology | $1.9M–$48M |
|
Verve Ventures
VC Fund
|
4 | Switzerland, Germany, France | Series A, Seed, Series B | Health Care, Software, Biotechnology | $1.4M–$43M |
|
O2h Ventures
VC Fund
|
4 | United Kingdom, Hungary | Seed, Series A | Biotechnology, Health Care, Pharmaceutical | $655k–$26M |
|
Dementia Discovery Fund
VC Fund
|
4 | United States, United Kingdom, Israel | Seed, Series A | Biotechnology, Health Care, Therapeutics | $5.9M–$77M |
|
11.2 Capital
VC Fund
|
4 | United States, Canada, United Kingdom | Seed, Series A, Series B | Software, Information Technology, Biotechnology | $1M–$53M |
|
Northstar Ventures
VC Fund
|
4 | United Kingdom, United States, Indonesia | Seed, Series A | Software, Health Care, E-Commerce | $39k–$9.7M |
|
Mercia Fund Managers
VC Fund
|
4 | United Kingdom, United States, Hungary | Seed, Series A | Software, Health Care, Biotechnology | $196k–$14M |
|
Beltrae Partners
VC Fund
|
4 | United Kingdom | Seed, Series A | Health Care, Life Science, Biotechnology | |
|
Cambridge Innovation Capital
VC Fund
|
4 | United Kingdom, United States, Ireland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2M–$73M |
|
Delin Ventures
VC Fund
|
4 | United Kingdom, Germany, Hungary | Seed, Series A, Series B | Software, Biotechnology, Information Technology | $1.3M–$100M |
|
Bioeconomy Capital
VC Fund
|
3 | United States, United Kingdom | Series A, Series B, Seed | Biotechnology, Life Science, Pharmaceutical | |
|
Nina Capital
VC Fund
|
3 | United States, United Kingdom, Germany | Seed, Pre-Seed, Series A | Health Care, Artificial Intelligence, Medical | |
|
Cambridge Angels group
VC Fund
|
3 | United Kingdom, United States, Estonia | Seed, Series A | Software, Health Care, Biotechnology | $270k–$9.5M |
|
Amadeus Capital Partners
VC Fund
|
3 | United Kingdom, United States, Spain | Series B, Seed, Series A | Software, Artificial Intelligence, Information Technology | $900k–$43M |
|
Hoxton Ventures
VC Fund
|
3 | United Kingdom, United States, Canada | Seed, Series A | Artificial Intelligence, Software, Health Care | $1.8M–$29M |
|
SIS Ventures
VC Fund
|
3 | United Kingdom | Seed, Series A | Biotechnology, Health Care, Medical | $1M–$19M |
|
Molten Ventures
VC Fund
|
3 | United Kingdom, United States, Germany | Series A, Series B | Software, Information Technology, Financial Services | $3.2M–$60M |
|
Wren Capital
VC Fund
|
3 | United Kingdom | Seed, Series A | Biotechnology, Health Care, Medical | $1.1M–$32M |
|
Tensor Ventures
VC Fund
|
3 | Czech Republic, United Kingdom, United States | Seed, Pre-Seed, Convertible Note | Information Technology, Software, Artificial Intelligence | $132k–$5M |
| Access all 510 VC funds in United Kingdom Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Philippines
Investor stats
- Total investments: 259
- Round size: Seed $982k–$5M; Series A $1.6M–$13M; Series B $2M–$46M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
- PhoreMost — PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savingsonto patients.
- Bramble Energy — Bramble Energy is an innovator energy technology company that designs and manufactures high-performance, low-cost, and fuel cell stack. The company ability to leverage the global high-volume PCB industry means that they are the first fuel cell company with the manufacturing capacity to supply gigawatts of fuel cell hardware, something the batteryindustry has spent many years and £B’s to achieve.Bramble Energy specifically uses a printed circuit board (PCB) technology to form the structural parts of the fuel cell. It also provides products including modular PCBFC stacks, H20:20W PCBFC system, custom design PCBFC, and 500W PCBFC stack.Bramble Energy was founded in 2016 and is based in London, England, United Kingdom.
Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Finland
Investor stats
- Total investments: 166
- Round size: Seed $1.3M–$12M; Series A $5M–$46M; Series B $8.5M–$168M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $327M in 2022
Portfolio highlights
- Pepgen — PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides,and they are advancing novel conjugate therapeutics to the clinic.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
- Quantum Motion — Quantum Motion delivers scalable silicon-based quantum computing using standard semiconductor manufacturing technology.
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 131
- Round size: Seed $393k–$5.9M; Series A $2.9M–$14M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2014
Portfolio highlights
- HonuWorx — HonuWorx is a subsea robotics company founded with a mission to replace surface vessels with underwater deployment platforms.
- NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
- Aquark Technologies — Aquark Technologies develops atom systems to develop quantum applications, including atomic clocks, sensors, and navigation systems. Aquark develops a technique to miniaturize cold atom systems using unique laser geometry that is based on more than 10 years of proprietary research at the University of Southampton.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Debt Financing
- Geography: United Kingdom, Australia, United States
Investor stats
- Total investments: 221
- Round size: Seed $327k–$3.7M; Debt Financing $18k–$3.7M
- Lead/follow: 59% lead, 41% follow
- Last fund: May invest from a new fund soon — raised $25M in 2018
Portfolio highlights
- Tourhub — tourhub - We collect tours from hundreds of suppliers around the world and provide an easy way for you to search and find those that are of interest.
- Antiverse — Designing biologics for 100 challenging targets
- Hope Macy — Hope Macy is the decisioning and origination layer that modern consumer lenders build on.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 309
- Round size: Series A $6M–$67M; Series B $10M–$120M; Series C $12M–$100M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Elicit Plant — We work with farmers around the world to meet the challenges of climate change and the impact of water scarcity on field crops.
- l'école — l'école AI is a computer vision-focused development platform. Its objective is to enable humans to use AI with purpose to change the future, beginning with a focus on speeding advances in life sciences using computer vision.
- EndoRon Medical — Endoron Medical develops an endovascular suture, like a device for the effective treatment of an abdominal aortic aneurysm.
IQ Capital is a Cambridge & London-based VC firm that invests in ‘deep tech’ companies capable of dominating their respective markets on a global scale. Initial investments at Seed and Series A range from £0.5m to £10m, with capacity for follow-on investment up to £30m through the Growth Fund. The team has achieved over 30 exits including toApple, Huawei, Google and Oracle.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Machine Learning
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 190
- Round size: Seed $1.3M–$13M; Series A $4.5M–$44M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Molyon — Molyon is creating the next-generation energy storage system: the lithium-sulfer battery. Molyon offers long-life lithium-sulfur batteries that have twice the energy density of existing lithium-ion batteries on the market.
- Nyobolt — Nyobolt develops high-power energy storage systems based on advanced lithium-ion battery technology designed for rapid charging and sustained high performance. The company focuses on battery systems that enable very fast energy replenishment, supporting applications where downtime needs to be minimized. Its technology combines specialized anodematerials, cell design, battery management systems, and power electronics to achieve high charge and discharge rates. The platform is used in sectors such as robotics, data centers, industrial equipment, and electric mobility where consistent high power delivery is required. It also develops integrated energy solutions that support demanding workloads like automated logistics systems and high-performance computing infrastructure. Nyobolt’s approach emphasizes optimizing cycle life, thermal stability, and energy density for repeated fast charging environments.
- Nu Quantum — Nu Quantum has been pioneering quantum networking technology since 2018. Our market-leading expertise is uniquely positioned to deliver a distributed quantum...
24Haymarket is an investment network which included several highly-experienced private equity and venture capital investors, seasoned entrepreneurs, and senior operators. Investing up to £5 million in growth companies in the UK and Europe. They invested their own capital in direct alignment with entrepreneurs and actively support their growthagenda and join the board of the companies in which they invest. Since inception in 2011, 24Haymarket has invested in more than 50 high-growth businesses.
Show more...Investment focus
- Industry: Health Care, Software, Information Technology
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 103
- Round size: Seed $714k–$3.8M; Series A $1.6M–$16M
- Lead/follow: 42% lead, 58% follow
Portfolio highlights
- DefiniGEN — Generate metabolic disease phenotypes in primary-like human cells using the best-in-class human iPSC differentiation platform. Find out more here!
- Previsico — Discover Previsico's real-time flood forecasting solutions, designed to mitigate risks for businesses and communities worldwide.
- proSapient — proSapient is a tech-led expert network that enables professionals to share insights with our clients (typically consultancies and PE firms) through calls, surveys and long-term engagements
Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Grant, Seed
- Geography: United Kingdom, United States, Japan
Investor stats
- Total investments: 311
- Round size: Seed $318k–$3.8M; Grant $104k–$4.8M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- Incremental Group — Incremental Group provides software consultancy and analytics services to clients in oil and gas, financial services, and the public sector.
- RAB Microfluidics — We diagnose early signs of failure in lubricated machinery and prevent equipment failure using our patented microfluidic technology and AI technology.
- Smart Green Shipping — smart green shipping alliance. economically, socially and environmentally superior shipping solutions.
The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, Italy, Germany
Investor stats
- Total investments: 33
- Round size: Seed $65k–$936k; Series A $1.8M–$4.1M
- Lead/follow: 67% lead, 33% follow
Portfolio highlights
- Maxwellia — A contraceptive pill, Lovima, is now available to buy without a prescription.
- Acea Health — Acea Health is a digital healthcare company developing an application called Flynotes - a new digital consent platform. Flynotes analyses a number of factors, including the patient’s background, to deliver personalised risks and benefits. Flynotes aims to be the go-to solution for consent in healthcare. .
- Nexus Labs (Surgical Teaching) — Nexus Labs is an interactive learning resource for medical students.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Series B, Seed
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 52
- Round size: Seed $1.8M–$17M; Series A $17M–$110M; Series B $24M–$131M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- Quell Therapeutics — Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cellengineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Brilliant Ideas. Brilliant People. Brilliant Minds.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note
- Geography: United Kingdom, United States, Spain
Investor stats
- Total investments: 145
- Round size: Seed $897k–$7.9M
- Lead/follow: 8% lead, 92% follow
- Last fund: Likely still investing — raised $23M in 2022
Portfolio highlights
- Rovco — Rovco designs an autonomous underwater vehicle or AUV and remotely operated underwater vehicle or ROV technologies and support services that optimizes how people manage and inspect subsea assets. Its technology offers the process of 3D photogrammetry that involves using high-resolution photos of a static object or site area taken from multipleangles and processed to generate a 3D vector model from point cloud data, enabling oil, gas, and renewables industry clients to evaluate their subsea assets for damage, corrosion or determining levels of marine growth and benefit from inspection related cost savings.
- Aloqia — Take control of your excess inventory with Aloqia. Resell, reuse, recycle, and prevent surplus while driving sustainability and supply chain resilience.
- Captura — Captura is harnessing the power of the ocean to heal the climate through Direct Ocean Capture technology.
Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 84
- Round size: Seed $1.3M–$3.9M; Series A $1.6M–$8.3M
- Lead/follow: 54% lead, 46% follow
Portfolio highlights
- BioCaptiva — BioCaptiva develops liquid biopsy technology devices to diagnose and monitoring to detect cancers.
- Cytomos — Cytomos develops and provides integrated, predictive analytics systems for intelligent bioprocessing in biopharma and cell therapy domains.
- Administrate — Administrate is a comprehensive, configurable training management platform that helps organizations streamline enterprise learning and development. Organize, deliver, plan, automate, analyze, and scale your training program effectively -- all through one system. Deliver multi-modality learner experiences, maximize training resources, anddemonstrate business results with insight-rich reporting. Hundreds of organizations serving millions of learners choose Administrate to manage their training program.
Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 103
- Round size: Seed $196k–$3.9M; Series A $1.3M–$5.2M
- Lead/follow: 22% lead, 78% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Zentraxa — NATURE ENGINEERED FOR PURPOSE Through millions of years of evolution, nature has found solutions to the most difficult problems. Inspired by the diversity of nature, we precision engineer bespoke biomaterials to meet the toughest challenges across
- Elemendar — Elemendar is building Artificial Intelligence that reads cyber threat reports by humans and turns them into industry-standard structured information.
- NuVision — NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at theUniversity of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.
Selvedge Venture operates as a venture capital firm investing for impact in age-related medical conditions.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Life Science
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, Singapore
Investor stats
- Total investments: 13
- Round size: Seed $1.4M–$9.6M; Pre-Seed $1.1M–$2.5M; Series A $3.5M–$30M
- Lead/follow: 54% lead, 46% follow
Portfolio highlights
- Exogene — Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.
- BIOS — BIOS Health is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals.
- Oxford Medical Products — Oxford Medical Products is a UK-based biotechnology start-up revolutionising the weight-loss treatment space with its hydrogel-based technology.
Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences. The programme aims to introduce new people to investing and investing in the healthcare/life sciences sector via investor workshops and introduce business angels to investment opportunities from highly-selected and trained companies.With aparticular focus on drug therapies, digital health and medical device technologies, Angels in MedCity brings potential investors together with life sciences experts in a programme aimed at both people who are new to investing and experienced investors who have little or no experience in the life sciences sector. The aim is to build investor understanding in the life sciences sector and support life sciences companies to gain funding to commercialise their ideas.Angels in MedCity has created a community of investors supported through a programme of investor workshops. Using case studies and tips from experienced investors in the field, the workshops explain how to identify and structure a good deal in the life sciences sector, as well as provide expert advice on tax breaks and legal issues.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Angel
- Geography: United Kingdom, United States
Investor stats
- Total investments: 18
- Round size: Seed $458k–$880k
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Atelerix — Discover Atelerix's hypothermic hydrogels for reliable cell preservation and ambient temperature shipping. Ensure fresh, viable cell samples.
- Clustermarket — The intuitive lab management system for all academic research facilities and industrial laboratories that need to efficiently manage equipment bookings.
- DynamX Medical — DynamX Medical has developed a reliable and inexpensive precancer screening system for rapid tissue biopsy analysis that can be operated point-of-care by nurses.
A new model for Venture Capital where every founder we back becomes a co-owner of the fund
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 111
- Round size: Seed $1.5M–$16M; Series A $7.9M–$33M; Series B $13M–$73M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Hofy — Use Hofy's equipment management platform to remotely supply, manage and maintain subscription workstations, while staying compliant.
- m3ter — m3ter is revolutionizing usage-based billing for B2B software scale-ups by automating complex bill calculations and integrations.
- Puraffinity — Puraffinity develops targeted materials for water treatment, focused on forever chemicals called PFAS. Our strategic intent is to provide 1 billion people with PFAS safe water by 2030
APEX Ventures is an early-stage venture capital fund that invests in start-ups grounded in unique and protectable technology. They provide support and resources and aims to develop their start-ups in their respective field. Their initial focus areas include digital media, business intelligence, cybersecurity, fintech, and the future of work.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Health Care
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, United Kingdom, Austria
Investor stats
- Total investments: 57
- Round size: Seed $1.3M–$8M; Pre-Seed $511k–$3M; Series A $5.2M–$28M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- Quibim — Quibim builds AI tools that turn MRI, CT and PET data into actionable predictions for hospitals and biopharma. Trusted in 230+ centers worldwide.
- GEMESYS — Gemesys creates a chip that functions similarly to the human brain in order to overcome processing constraints and empower AI with the hardware it needs to complete its destiny
- OroraTech — From safeguarding forests and ecosystems to protecting communities and critical assets, OroraTech's advanced technology and reliable insights address challenges, mitigate risks, and drive meaningful impact.
Techstart Ventures is a first-cheque investor for extraordinary founders pursuing uncapped global opportunities.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Pre-Seed
- Geography: United Kingdom, Ireland, United States
Investor stats
- Total investments: 153
- Round size: Seed $183k–$3.5M; Pre-Seed $410k–$1.6M
- Lead/follow: 45% lead, 55% follow
Portfolio highlights
- Biomage — Cellenics is a single cell data analysis software. It starts with a 10X Chromium count matrix produced by Cell Ranger. Unlike Loupe, the Cellenics platform is an end-to-end tool, which allows you to perform single cell RNA-seq data processing, multiple sample data integration, visualisation, differe
- Heysummit — Build beautiful virtual events, conferences, courses, and more to engage with your audience and grow your community through events-based marketing.
- BrainWaveBank — BrainWaveBank has developed a first-in-class wearable electroencephalography (EEG) device to conveniently and non-invasively measure the mechanisms that underpin neurological disorders and therapies. Our platform can securely gather, store and analyse data from many thousands of users, building neurocognitive profiles of individuals and populationsor demographic groups. This easy-to-scale and distributable approach will help clinical professionals to transform our understanding of brain health and develop the next generation of treatments.BrainWaveBank was founded in January 2015 and has offices in Belfast , Northern Ireland and Dublin, Ireland.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 189
- Round size: Series A $3.7M–$140M; Series B $15M–$114M; Series C $22M–$150M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Turning Point Therapeutics — The Investor Relations website contains information about Turning Point Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
- River Vision Development — River Vision Development develops RV001, a protein therapy for the treatment of Graves’ Orbitopathy (GO). River Vision Development was founded in 2011 and is based in New York, New York.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Therapeutics
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Australia
Investor stats
- Total investments: 191
- Round size: Seed $393k–$7.6M; Series A $2M–$23M
- Lead/follow: 21% lead, 79% follow
- Last fund: May invest from a new fund soon — raised $125M in 2014
Portfolio highlights
- Eight19 — Eight19, located in Cambridge, UK, develops and manufactures plastic photovoltaics for energy harvesting, for the internet of things and for off-grid applications. Through the innovative use of industry-standard, high-volume, roll-to-roll processes and solution-based organic photoactive materials, the company has a highly cost-effective route forscaling-up its technology to supply the largest markets. Eight19 is currently producing modules on a small scale for commercial partners with applications in indoor energy harvesting for wireless sensor and controllers, signage and display, and outdoor power for portable electronics. Our plastic PV modules benefit from flexibility, thinness, light-weight and robustness.
- Alimetry — Alimetry is a health technology startup based in Auckland, New Zealand, developing breakthrough solutions for diagnosing disorders of gastrointestinal (GI) function.
- AccelerComm — Our patented, market-leading IP solutions for 4G and 5G are configurable for quick, high-performance implementations across a wide range of applications.
Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 48
- Round size: Seed $531k–$8.5M; Series A $2.6M–$40M; Series B $2.4M–$55M
- Lead/follow: 48% lead, 52% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Leucid Bio — CAR T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers.
- AdoRx Therapeutics — AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer based on modulation of the adenosine pathway. High levels of adenosine in the tumour microenvironment enable cancer to evade the immune system. AdoRx’s lead programs are focused on the design of “fit for purpose” adenosine receptor antagonists that will overcome the effectsof high adenosine levels. AdoRx Therapeutics is a UK-based drug discovery company and backed by investment from Epidarex Capital and Sixth Element Capital. The AdoRx leadership team have discovered in excess of 25 clinical candidates and have greater than 60 years combined experience of drug discovery in biotech and pharma.
- Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.
Speak with our Entrepreneurship and Investment teams, who can help you find sources of finance, engage with funders and secure investment to grow your business.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 208
- Round size: Seed $327k–$3.1M; Series A $1.6M–$7M
- Lead/follow: 11% lead, 89% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
- IOTech — Discover IOTech Systems. Deploy, manage, and scale AI-driven, data-rich industrial systems at the edge with our open edge data platform.
- Administrate — Administrate is a comprehensive, configurable training management platform that helps organizations streamline enterprise learning and development. Organize, deliver, plan, automate, analyze, and scale your training program effectively -- all through one system. Deliver multi-modality learner experiences, maximize training resources, anddemonstrate business results with insight-rich reporting. Hundreds of organizations serving millions of learners choose Administrate to manage their training program.
Maven is one of the UK's leading private equity and investment firms. We provide essential capital and expertise to help businesses unlock their potential.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 193
- Round size: Seed $655k–$5.2M; Series A $2.6M–$25M
- Lead/follow: 74% lead, 26% follow
Portfolio highlights
- Kani — Kani Reporting and Reconciliation is a set of tools to help you report and reconcile transactions and movement of funds. By integrating directly with your processor Kani quickly and accurately provides the clarity you need; whether it’s a QMR, QOC, Settlement Report, or even a Custom Reconciliation, Kani contextualises and gives you full controlover your data.
- Bright — Bright Network has a range of graduate careers available. Whatever the sector you want to go into Bright Network will help you find your dream job.
- Chorus Intelligence — Trusted suppliers of digital investigation software that enables our customers to confidently turn data into intelligence and evidence.
Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, Australia, Singapore
Investor stats
- Total investments: 84
- Round size: Seed $152k–$2.6M; Series A $2M–$15M
- Lead/follow: 74% lead, 26% follow
- Last fund: Likely still investing — raised $1.4M in 2022
Portfolio highlights
- HeadBox — HeadBox connects corporate event planners with 100,000+ unique, inspiring, iconic, and creative spaces worldwide for meetings and events.
- Touch Biometrix — Welcome at Touch Biometrix. Find out more about The Future of Fingerprint Biometrics!
- Spotlight Pathology — Spotlight Pathology develops decision support tools powered by artificial intelligence (AI) to help in the diagnosis of blood cancers.
Helping individuals and institutions invest in Venture Capital, Infrastructure and Media companies since 1999.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 141
- Lead/follow: no public data
Portfolio highlights
- Egregious — Egregious is an advanced research & intelligence lab established to defend humans from AI and provides narrative intelligence solutions across the public and private sectors to protect organisations and online users from malign influence using AI-driven data acquisition, insights, and engagement.
- Arcube — We make sure all travellers, frequent and infrequent, make the most of travel loyalty programs, using our data-driven approach, airlines can understand their customers and provide hyper-personalised offerings to boost value and retention.Arcube uses a data-driven approach to make the most of airline loyalty programs for both frequent andinfrequent flyers. Our software allows airlines to understand their customers and provide hyper-personalised offerings to boost value and retention at no extra cost to the airline.
- FinCrime Dynamics — Our mission is to help make the world’s financial system safer through rapid deployment of effective AI for financial crime analytics, enabled by enriched synthetic data that captures the dynamics of fraud and money laundering and loads them into tailor-made scenarios that explore diverse threats that financial organisations are exposed to.Thisgoal has taken us to the forefront of Synthetic Data and Fincrime Analytics, and we are proud to have in our team people that have helped shape the state-of-the-art of these fields.Keywords: Finacial services, AML, Synthetic Data, Fintech, Machine learning, Big data, Simulation, Fraud Analytics, Compliance
GV supports innovative founders moving the world forward.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 1029
- Round size: Seed $1M–$15M; Series A $5.4M–$88M; Series B $15M–$107M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $100M in 2014
Portfolio highlights
- Smarterer — Individuals and Fortune 500 companies use Smarterer to help close the gap between the skills they have and the skills they need. Their dynamic assessment engine leverages the freshest crowdsourced tests around, to rapidly pinpoint skill level with a credible score. In November 2014, Pluralsight, the global leader in online learning for serioussoftware developers, IT specialists and creative technologists, acquired Smarterer. As the world's largest curated e-learning library for professionals, the company offers instant access to more than 3,500 courses authored by top experts. Smarterer will continue to power crowdsourced assessments for freelancer marketplaces, e-learning providers and enterprise companies anywhere people need to prove their skills to connect with professional opportunities. The Smarterer community has answered over 56 million during 1.7 million test sessions, across hundreds of tests.
- Zest — Give your shoppers the swiftest gifting experience in ecommerce. With Zest, shoppers on your site can send a gift to anybody, anywhere with just a link.
- EpiBiologics — EpiBiologics develops first-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology.
Southern Angel Investors Club, combining Surrey investors Club & Angels 5K, are entrepreneurs who understand what new businesses need.
Show more...Investment focus
- Industry: Biotechnology, Software, Medical
- Stage:Seed, Angel
- Geography: United Kingdom
Investor stats
- Total investments: 26
- Round size: Seed $79k–$1.3M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Celixir — Celixir is a developer of regenerative medicines created to change the lives of patients in need. The company's medicines consists of iMP cells, platelet lysate and PML cells to treat patients with ischaemic heart disease, injured tendons near the surface of the skin and mild to moderate heart failure respectively, enabling medical researchersto discover breakthrough medicines that aim to change the standard of medical care for patients.
- Novastone Media — Novastone enables instant chat across mobile and web to move customer conversations from email. Novastone’s white label chat solutions, built by financial industry experts, deliver on all these requirements, seamlessly moving organisations’ most valuable relationships from the inbox into a chat conversation.
- Geektastic — Geektastic guarantees hiring teams only meet high calibre candidates. Our technical code challenges quickly identify the most talented software engineers.
AlbionVC supports visionary founders and technologies with long-term capital and scale-up know-how. Founded in 1996, it was amongst the first to back leading global success stories such as Booking.com, Egress, Quantexa and Oviva. With £1bn in AUM and over 100 exits successfully realised, it funds venture breakthroughs that drive real outcomes forfounders, investors and society. AlbionVC is the technology investment arm of Albion Capital Group, which is authorised and regulated by the Financial Conduct Authority. For more information please visit: https://albion.vc/
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Series A, Seed
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 164
- Round size: Seed $2.2M–$13M; Series A $3.8M–$20M
- Lead/follow: 41% lead, 59% follow
Portfolio highlights
- Runa — Businesses from every walk of life use rewards to acquire, retain and thank customers but the current process is broken. Sending rewards, incentives and non-cash payouts is manual, expensive, time-consuming and error-prone. WeGift changes this. Operating in more than 30 countries, in 22 languages, 20 currencies, with over 700 brand partners, andhundreds of clients, like Perkbox, Sodexo, New Look and Halfords among others, WeGift’s cloud-based, open API solutions allow businesses to transfer value to consumers, in real-time and globally. Established in 2016, WeGift is backed by leading entrepreneurs and investors.
- Hussle — Gym membership with total flexibility. Gym passes to no contract gym memberships that you can use in thousands of gyms across the UK. Gym and swim wherever you want to. Stop and start whenever you like.
- Clear Review — Enable conversations to drive meaningful relationships and ensure employees feel supported to reach their goals, so organisations can achieve what matters most.
Playfair is a sector agnostic fund focused exclusively on pre-seed investing. Based in London, Playfair invests across the UK and Europe with an intentionally high conviction, low volume approach: making six investments a year out of its third $70m fund and preserving time, capital and resource to help companies post-investment. Our 78% Series Agraduation rate is ~3x industry average. Playfair has backed 100+ companies since 2013, including Thought Machine, Orca AI, Protex AI, StackOne and Nory.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, E-Commerce
- Stage:Seed, Series A, Pre-Seed
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 132
- Round size: Seed $1M–$7.7M; Pre-Seed $700k–$3.1M; Series A $2.7M–$20M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- Nory — Revolutionise your restaurant with Nory's restaurant management software. Streamline operations, boost profits, and enhance decision-making in one platform.
- Protex AI — Protex AI develops an AI-powered proactive health and safety technology that enables an injury-free industrial workplace. The company allows EHS teams to adopt proactive safety cultures and in doing so realize an injury-free workplace.
- Passionfruit — Join hundreds of the best startups around the world and use Passionfruit to hire freelance marketing specialists on-demand.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Formic Ventures is a diversified venture capital firm that makes early-stage investments in biotechnology startups focused on human longevity as well as technology startups and companies that make human lives more meaningful.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Biopharma
- Stage:Seed, Series A
- Geography: United States, United Kingdom, Hong Kong
Investor stats
- Total investments: 39
- Round size: Seed $1.3M–$12M; Series A $17M–$61M
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- SonoThera — Explore therapeutic ultrasound for non-invasive, targeted genetic medicine delivery that improves precision and biodistribution. Learn more.
- cheMastery — Echo handles repetitive tasks with accuracy and precision, allowing your chemists to tackle high-value challenges.
- Biogenesis — Clinical research platform tailored towards industry sponsors, clinical research sites & patients
We provide venture capital investment for the people, ideas and industries that will change the world. Learn about what we do and the kind of founders we back.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Seed, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 369
- Round size: Seed $1.9M–$13M; Series A $3M–$21M; Series B $7.5M–$48M
- Lead/follow: 57% lead, 43% follow
- Last fund: May invest from a new fund soon — raised $101M in 2019
Portfolio highlights
- Wazoku — Wazoku - Where Innovation Works Wazoku
- CertiVox — CertiVox solutions deliver simple, powerful information security to all things Internet (mainframes, too!), protecting business and individual privacy through the cloud and at rest. CertiVox was founded in 2009 to provide technology and services based on a simple belief: that everyone deserves the right to secure their information exchangessimply and easily. CertiVox's leading-edge encryption, key management and identity management solutions are currently in use at hundreds of the world’s leading corporations and used by individuals across the globe to protect their privacy.The companies passion is to create and share unique, cutting-edge cryptographic innovations for enterprise cloud computing and all things Internet. CertiVox are the only company in the global market today that has the technology in place to arm businesses and individuals with easy-to-use certificateless security solutions for any device and platform.Whether you are a business that wants to safeguard your company’s intellectual property, an ISV or SaaS provider that needs to embed cryptography and key management into your application, or an individual who wants to preserve the privacy of your personal data, CertiVox gives you the power to secure your information for all things Internet.CertiVox’s leading-edge solutions – including MIRACL (Multiprecision Integer and Rational Arithmetic C/C++ Library) Cryptographic SDK, on-demand encryption Key Management Service (KMS) and Identity Management Service (IDMS) – enable cloud service providers, independent software vendors (ISVs), communication providers, and smart device and semiconductor manufacturers to secure their voice and data communication solutions with ease.The PrivateSky Secure Information Exchange Service (SIX) gives individuals, businesses and their partners and customers easy-to-use tools to quickly encrypt email, files and documents without complex infrastructure or user burden. Compliance with mandatory encryption and privacy statues has never been easier.The bottom line: CertiVox's revolutionary certificateless cryptography, identity and key management solutions have taken the hassle out of Internet security, making it easy to securely exchange your information in any form, any time.
- Mojo — Join 600,000+ men worldwide using AI-powered coaches to build a performance mindset and take back control of their love lives.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 260
- Round size: Seed $1.4M–$10M; Series A $2.3M–$17M; Series B $4.2M–$43M
- Lead/follow: 14% lead, 86% follow
- Last fund: Likely still investing — raised $66M in 2022
Portfolio highlights
- Sleepiz — Sleepiz is a Zürich based startup with the aim to enable the medical community to take healthcare into the home environment. Sleepiz provides an easy and comfortable to use solution with a device that is simply placed on the bedside table. The device operates in a non-contact fashion and measures movements originating from heart contractions andbreathing patterns as well as body motions with medical grade accuracy.By making use of wireless millimeter wave technology, sensor fusion and artificial intelligence Sleepiz will in the future not only able to diagnose sleep disorders, but also to perform long-term monitoring. Thereby, the progression of chronic diseases can be monitored to allow faster intervention and better treatment.
- Biograil — Biograil, founded in 2019 and led by CEO Karsten Lindhardt, is using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The Biograil device avoids mechanical moving components and makes use of the body’s own peristaltic forces to facilitate the delivery ofthe biologic efficiently into the gastrointestinal wall.
- iMusician — iMusician offers music distribution, promotion, mastering, and monetization for independent musicians & labels. Get on Spotify, Apple Music, Amazon, TikTok & many more.
Transforming UK biotech breakthroughs into impact. o2h Ventures offers SEIS/EIS and growth-stage funds to back visionary teams from seed to clinical success.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Seed, Series A
- Geography: United Kingdom, Hungary
Investor stats
- Total investments: 39
- Round size: Seed $655k–$7.9M; Series A $1.9M–$26M
- Lead/follow: 46% lead, 54% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Atelerix — Discover Atelerix's hypothermic hydrogels for reliable cell preservation and ambient temperature shipping. Ensure fresh, viable cell samples.
- Neurocentrx — Neurocentrx is a specialty pharma company, developing and in-licensing products in pain, palliative care, psychiatry and mood disorders.
- Alevin Therapeutics — Our mission is to develop safe and effective medicines for patients with life-threatening diseases through targeted integrin therapies
SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Seed, Series A
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 50
- Round size: Seed $5.9M–$20M; Series A $7M–$77M
- Lead/follow: 42% lead, 58% follow
- Last fund: May invest from a new fund soon — raised $337M in 2018
Portfolio highlights
- Violet Therapeutics — Violet Therapeutics is a healthcare company that operates in stealth mode.
- Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
- Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.
In physics, 11.2 km/s is the escape velocity from Earth's gravity. They focus on emerging technologies such as AI, cybersecurity, robotics, quantum, new space, computational therapeutics, synthetic biology. They believe great people are leading indicators of a company's success. 11.2 Capital’s technical background, operationalexperience, and a strong network of amazing advisors and international partners particularly in Asia deliver a unique set of resources to entrepreneurs. While they are happy to help companies across the full range of early-stage company questions, areas where they concentrate include technical recruiting, partnerships (OEM and distribution partnerships for smart hardware companies, data partnerships for data-driven healthcare companies), customer introductions (CISO introductions for security companies, provider introductions for healthcare companies), and follow-on financings.
Show more...Investment focus
- Industry: Software, Information Technology, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 57
- Round size: Seed $1M–$12M; Series A $7.3M–$26M; Series B $15M–$53M
- Lead/follow: 12% lead, 88% follow
Portfolio highlights
- Human Security — HUMAN is a cybersecurity company that protects enterprises from bot attacks to keep digital experiences human.
- CryptoNumerics — HIPAA, GDPR and Data Residency requirements restrict your ability to conduct data science. CryptoNumerics removes these restrictions. CryptoNumerics enables you to create privacy protected datasets with quantifiable privacy risk. In addition, you can build statistical and machine learning models that protect people’s privacy. Our team consists ofengineers and visionaries with previous experience in C-Level roles at Fortune 500 companies, founding teams of venture backed growth stage start-ups, and accomplished R&D leaders.
- Coalesce Automation — Coalesce is the only data transformation tool built for scale. Evolve your transformations and empower your entire data team.
Northstar Ventures invests venture capital in early and later stage, high growth companies tackling global challenges, focusing on climate tech and healthy ageing.
Show more...Investment focus
- Industry: Software, Health Care, E-Commerce
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Indonesia
Investor stats
- Total investments: 190
- Round size: Seed $39k–$1.8M; Series A $851k–$9.7M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- H2CHP — H2CHP's Free Piston Engine Technology enables your transition to green energy with the reliability & confidence of fuel flexibility.
- NunaBio — NunaBio operates as a privately-owned specialist DNA development company. NunaBio engaged in CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organisation) activities.
- CellRev — high expertise in the designing and testing of self-assembling peptides providing different benefits when culturing adherent cells in vitro.
Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Hungary
Investor stats
- Total investments: 135
- Round size: Seed $196k–$2M; Series A $2M–$14M
- Lead/follow: 67% lead, 33% follow
- Last fund: May invest from a new fund soon — last raise in 2013
Portfolio highlights
- Sen — Sen's vision is to democratize space using video to inform, educate, inspire and benefit all humanity. Sen's mission is to stream real-time videos from space to billions of people, gathering news and information about Earth and space and making it universally accessible.
- 4D Medicine —
- Role Mapper Technologies — Automate and transform how you design and manage job descriptions across your organisation. Hire, retain and grow an inclusive and diverse workforce with AI powered Intelligent Job Design.
Independent Corporate Finance Advisors & Private Equity Investors
Show more...Investment focus
- Industry: Health Care, Life Science, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 4
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Neurovalens — Neurovalens delivers innovative solutions in the field of neuroscience, bioscience and neurophysiology.Neurovalens has received support from Invest NI under the European Union’s Investment for Growth and Jobs Programme. The project, recorded on the ERDF beneficiaries’ website, will be implemented over the next one year, undertaking research anddevelopment activities aimed at improving the competitiveness of the business.
As a team, we have a passion for science and its potential to drive change. Through our expertise and our position in one of the country's most powerful science and technology ecosystems, we're able to identify and support the most promising entrepreneurs in knowledge intensive businesses and help them achieve their vision.With our financial backing and expert guidance, we're excited to enable the pioneers in life sciences and deep tech to create world-leading companies whose unique ideas bring financial success and global impact.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 97
- Round size: Seed $3.9M–$23M; Series A $2M–$73M; Series B $8.5M–$65M
- Lead/follow: 36% lead, 64% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Immutrin — Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively andspecifically remove established amyloid fibrils.
- Trent AI — Trent AI creates AI applications and agent security management software. It aids in risk assessment and mitigation in systems utilizing autonomous or semi-autonomous software agents. The company's technology monitors agent activity across APIs, tools, and workflows. It continuously assesses security posture via iterative scanning andcontextual understanding of system architectures.
- Forefront RF — Forefront RF tunable duplexer technology expands the accessibility of all mobile devices by unlocking SDR capabilities in the RFFE front end.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!We are partnering with remarkable entrepreneurs and scientists on the mission of our lives: elevating humanity.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, Germany, Hungary
Investor stats
- Total investments: 31
- Round size: Seed $1.3M–$9.2M; Series A $5.1M–$30M; Series B $15M–$100M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Turbine — Turbine is virtualizing biological experiments with AI to accelerate drug discovery and enhance clinical translatability.
- Agile Analog — Agile Analog is a company with a mission to transform the landscape of the Analog IP market space.
- Athernal Bio — Athernal Bio is developing targeted immunotherapies to treat blood cancer precursor conditions before cancers become established.
Bioeconomy Capital invests in early-stage companies with the goal of accelerating the biotechnology revolution. Based on its startup operational expertise, product development experience, and globally recognized strategic analysis, it has developed a blueprint for building and deploying technological capabilities that will become a criticalinfrastructure of the 21st-century economy.The company's proprietary blueprint is the distillation of the fund managers' five decades of combined experience in synthetic biology and other engineering fields and cannot be readily duplicated. Prior investments include Zymergen, Riffyn, Synthace, RoosterBio, Arzeda, Bellwether Bio, EdenWorks, and Lumen Biosciences.
Show more...Investment focus
- Industry: Biotechnology, Life Science, Pharmaceutical
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom
Investor stats
- Total investments: 19
- Lead/follow: no public data
Portfolio highlights
- MicroByre — MicroByre is a platform for bacterial domestication. Their automated characterization pipeline gathers the oft-overlooked data that highlights unleveraged bacteria that meet functional industrial criteria. That is, they rapidly find the bacteria with naturally unfussy eating habits and evolution-honed metabolisms that have the potential to convertunrefined biomasses into commodity chemicals at vastly improved efficiencies compared to extant fermentation processes. They select from these functionally de-risked bacteria those which can be directly genetically modified to improve their cost profiles — even if they have never been engineered before. The data from our unique characterization pipeline informs the minimally precise genetic modifications necessary to increase pliability and yield, eliminate nutritional additives, maximize feedstock utilization, and improve contamination tolerance & phage resistance. MicroByre gives biomass conversion a truly competitive edge against petrochemical synthesis.MicroByre’s platform bridges the gap between the promising and the profitable in synthetic biology and bioengineering. A unique combination of resources and skills makes MicroByre a valuable potential partner for companies of all sizes and industries. They collaborate to define project scope to match a mutually agreeable business model, which could be a fee for service, license agreement, or joint development agreement.
- Tandem PV — Discover the future of sustainable energy with Tandem PV, a leader in perovskite solar technology and innovative solar energy solutions.
- Parse Biosciences — Parse Biosciences is providing researchers with the ability to perform single cell sequencing with unprecedented scale and ease. Learn more about how you can use the most scalable single cell platform on the market without the need for custom instrumentation.
We deploy early stage capital to fuel the growth of need-driven health technology companies.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Medical
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 80
- Lead/follow: no public data
Portfolio highlights
- Datamonk — AI-powered PACS migration platform that automates secure and fast transfers of medical imaging data. Migrate up to 10TB per day and use AI agents for data validation and quality assurance.
- io Health — Io Health Technologies LLC provides AI-driven tools for home health documentation and workflow automation in healthcare.
- Sober Sidekick — Gamified peer to peer support
The Cambridge Angels are a group of high-net worth investors who have proven experience as successful entrepreneurs in internet, software, technology and bio-technology. Members invest in and mentor high quality start-up and early-stage companies in these sectors in the Cambridge (UK) area and throughout the UK.Typical funding requirements thatthe Cambridge Angels meet are in the range of £50,000 to £500,000 - although it is worth noting that several of their portfolio companies have received more than £1m in funding from their Members over several funding rounds.Their Members have been responsible for a large number of the “Cambridge Phenomenon” success stories over recent years. Therefore, in addition to providing funding for early-stage companies, the Cambridge Angels also offer start-ups the considerable benefit of a wide range of expertise, contacts and directly relevant experience in establishing and growing entrepreneurial businesses successfully.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Estonia
Investor stats
- Total investments: 131
- Round size: Seed $270k–$2.9M; Series A $2M–$9.5M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- MNS —
- FLIT — Unfold Your Next Adventure. Discover the compact folding electric bike purpose-built for commuters, urban explorers and weekend tourers.
- AVIEL Intelligence — Prevent APP fraud with the highest quality of intelligence. Use AVIEL intelligence to help prevent your customers making payments to scammers - and from receiving payments related to scams.
Amadeus Capital Partners, Venture Capital For Technology Companies. We Back Entreprenuers To Win. Contact Our Experienced Team Of Investors Today
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Series B, Seed, Series A
- Geography: United Kingdom, United States, Spain
Investor stats
- Total investments: 234
- Round size: Seed $900k–$9.2M; Series A $2.6M–$30M; Series B $6.8M–$43M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — raised $88M in 2023
Portfolio highlights
- Pimloc — Pimloc's deep learning platform enables private businesses and public organisations to protect sensitive or personal data in video, to maintain safe online environments and to manage video security.
- XYZ Reality — XYZ Reality - The world's first Engineering-Grade augmented reality system for construction.
- Altana — Altana powers trusted trade for governments and businesses worldwide. Map supply chains, manage tariffs, ensure compliance, and build resilience with AI.
Hoxton Ventures focuses on startups that either disrupt existing industries or invent entirely new market categories. Hoxton typically invests between $500,000 and $5 million into pre-seed, seed, and Series A stage companies, and follows its capital through the life of the company. The firm is based in London and invests all across Europe.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Health Care
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Canada
Investor stats
- Total investments: 129
- Round size: Seed $1.8M–$12M; Series A $5M–$29M
- Lead/follow: 43% lead, 57% follow
Portfolio highlights
- Preply — Looking for a tutor? Preply is the best platform for private online lessons with a flexible payment system and affordable prices. Book your first lesson.
- Fabrica AI — Fabrica AI offers a revolutionary platform for faster robot development, using custom hardware designs and learned optimal control to increase efficiency while minimizing complexity and cost. With a vision for a future where robot development takes days, not years.
- Peptone — We are the first in class pre-clinical translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered targets.
SIS Ventures has been created with the overall aim of supporting and growing high impact organisations through access to mission-aligned investment. SIS Ventures has a goal of becoming the go to investor and partner for social entrepreneurs. The fund will offer conventional financial returns alongside social and/or environmental returns byinvesting either equity or debt into purpose driven companies.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 33
- Round size: Seed $1M–$5.2M; Series A $2.8M–$19M
- Lead/follow: 3% lead, 97% follow
- Last fund: May invest from a new fund soon — raised $1M in 2018
Portfolio highlights
- Dxcover — Dxcover are a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life.
- MiAlgae — MiAlgae is a new-age microalgal production company that aims to revolutionize the £340 billion global livestock feed industry by producing microalgal products – through the remediation of wastewater – as nutrient supplements for fishmeal in livestock feeds. Their microalgal products are high in omegas and proteins, both of which are required forthe production of many livestock feeds, especially in the aquaculture sector.Their production methodology uses circular economy to reduce the operating costs involved in the production of microalgae and as such allows them to compete with other supplements currently on the market.
- Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
Molten Ventures is a leading British venture capital firm backing Europe’s highest-growth private technology companies. Our expert investment team stay ahead of the curve, identifying transformative trends and next-generation companies before they break through. We combine multiple pools of capital to invest at all stages of the businesslifecycle—from seed and early stage to growth and late stage—focusing on disruptive sectors like Spacetech, Fintech, and AI. Our strategy is simple: back bold ideas, scale them with capital and expertise, and unlock high-value exits—whether through strategic acquisitions, trade buy-outs, or IPOs. Since our 2016 IPO, we’ve delivered strong realised returns, reinvesting into the next wave of innovation—creating a virtuous cycle of growth and value.
Show more...Investment focus
- Industry: Software, Information Technology, Financial Services
- Stage:Series A, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 221
- Round size: Series A $3.2M–$30M; Series B $7.9M–$60M
- Lead/follow: 52% lead, 48% follow
- Last fund: May invest from a new fund soon — raised $6.1M in 2011
Portfolio highlights
- Manna Air Delivery — Drone delivery made simple
- PrimaryBid — PrimaryBid builds technology that connects companies with their retail investor communities. We power smart retail inclusion in global capital markets.
- SatVu — SatVu captures high resolution thermal data from space for a safer and more sustainable Earth.
Wren is an angel investor in science, engineering and software. They founded Wren in 2011 and have invested in 50 companies so far.Wren is well known in the early stage investment community and has co-invested with a wide range of both angel and institutional investors. From software and semiconductors to genome editing, and from medical devicesto satellites, they are interested in sectors where technical ingenuity and hard work can produce long term value. They look for people with a deep understanding of their markets. The founders they invest in are smart and they get things done.Wren typically invests £50,000 to £200,000 per funding round. Difficult problems take time to solve, so they are patient with their investments. Their aim is to get deals done and they take a pragmatic approach to doing so.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 33
- Round size: Seed $1.1M–$5.2M; Series A $2M–$32M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Spotta — Spotta's smart pest systems help pest control monitor and identify pests. Solutions for hospitality, care homes, agriculture, farming and forestry.
- SenseAI —
- Monument Therapeutics — Monument Therapeutics is a biotechnology company intended to develop drugs to treat serious diseases of the central nervous system.
New generation venture capital investing into combinatorial technologies
Show more...Investment focus
- Industry: Information Technology, Software, Artificial Intelligence
- Stage:Seed, Pre-Seed, Convertible Note
- Geography: Czech Republic, United Kingdom, United States
Investor stats
- Total investments: 32
- Round size: Seed $1.4M–$5M; Pre-Seed $132k–$3M
- Lead/follow: 44% lead, 56% follow
Portfolio highlights
- AppFactor — AppFactor is an intelligent, AI powered transformation platform to empower architects and engineers to re-factor and re-architect applications to solve legacy infrastructure problems and application delivery.
- DYNANIC — DYNANIC is an IT firm that provides custom development, consulting, and training for programmable logic and its verification.
- Tatum — Next-gen infrastructure with support for 28+ blockchains in a simple, unified REST API. Any developer can be a blockchain developer with Tatum.
Life Science VC funding in United Kingdom at a glance
Stats across 456 deals from 510 investors.
Access all 510 VC funds in United Kingdom Life Science startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science VC Funds in United Kingdom investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 510 VC funds investing in United Kingdom Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!